LGK974 is a potent and specificinhibitor of O-acyltransferase Porcupine (Porcn) that acylates Wnt proteins required for their biological activities. The structure of LGK974 was recently published and found not only more potent than the IWP-1, 2, 3 or IWP-4 Porcn inhibitors, but LGK974 is also suitable for in-vivo studies and is currently in Phase I clinical trials to treat cancers.
Purity: Greater than 99% as determined by LC/MSanalysis.
Biological Activity: Biological activity has been determined. In a co-culture assay measuring the activation of the TCF reporter gene by Wnt3a-secreting cells, this compound gives IC50 of 0.2to 0.6nM. Pan and colleagues reported antitumor activity of LGK974 in xenograft models of human head and neck as well as pancreatic tumors when dosed at 1 to 10 mg/kg orally.